These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28331745)

  • 1. Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey.
    Özmen V; Atasoy A; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkkdoğan A; Cabioğlu N; Şen F; Saip P
    J Breast Health; 2016 Jul; 12(3):107-111. PubMed ID: 28331745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.
    Ozmen V; Atasoy A; Gokmen E; Ozdogan M; Guler N; Uras C; Ok E; Demircan O; Isikdogan A; Saip P
    Cureus; 2016 Mar; 8(3):e522. PubMed ID: 27081583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
    Özmen V; Çakar B; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkdoğan A; Saip P
    Eur J Breast Health; 2019 Jul; 15(3):183-190. PubMed ID: 31312795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
    Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
    Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
    Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
    Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
    Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
    Thibodeau S; Voutsadakis IA
    Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation oncotype DX
    Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
    Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
    Wang J; Chen H; Koenig J; Wu Y; Bedrosian I; Arun B; Ding Q; Khazai L; Resetkova E; Huo L; Sneige N; Albarracin C
    Breast Cancer Res Treat; 2024 Jan; 203(1):73-83. PubMed ID: 37751078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors That Predict Biological Aggressiveness in Estrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative / Lymph Node-Negative Breast Cancer.
    Arthur LE; McMann AH; Slattery LN; Fuhrman GM; Mackey AM; Rivere AE; Corsetti RL
    Ochsner J; 2020; 20(4):381-387. PubMed ID: 33408575
    [No Abstract]   [Full Text] [Related]  

  • 14. Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients.
    Huang Z; Qin Q; Xia L; Lian B; Tan Q; Yu Y; Mo Q
    Cancer Manag Res; 2021; 13():587-593. PubMed ID: 33519238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX
    Aktas B; Bankfalvi A; Heubner M; Kimmig R; Kasimir-Bauer S
    Mol Clin Oncol; 2013 Nov; 1(6):1049-1054. PubMed ID: 24649291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.
    Alkushi A; Omair A; Arabi H; Masuadi E; Abualkhair O
    Breast Cancer (Auckl); 2020; 14():1178223420977848. PubMed ID: 33343196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
    Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
    Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
    Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.